温补脾肾法治疗肺癌免疫治疗相关性不良反应的临床疗效观察  

Clinical efficacy of warming spleen and kidney therapy on immunotherapy related adverse reactions of lung cancer

作　　者：杨勃 YANG Bo

机构地区：[1]湖南省邵阳市中医医院,湖南邵阳422000

出　　处：《中医临床研究》2022年第16期95-97,共3页Clinical Journal Of Chinese Medicine

基　　金：湖南省中医药科研计划项目:温补脾肾法治疗肺癌免疫治疗相关性腹泻(脾肾阳虚型)临床疗效观察(2021155)。

摘　　要：目的:观察温补脾肾法治疗肺癌免疫治疗相关性不良反应的临床疗效。方法:选取2020年1月-2021年1月收治98例肺癌患者作为本次研究对象,应用随机数字表法均分为对照组和治疗组。对照组口服泼尼龙治疗,治疗组加用温补脾肾法治疗。比较两组治疗后的临床疗效、不良反应发生状况,治疗前后的中医证候积分、卡氏功能状态评分(Karnofsky Performance Scale,KPS)评分、免疫功能。结果:相比对照组,治疗组的总有效率显著更高(P <0.05)。治疗后,两组皮疹、腹泻、肝功能损害、恶心呕吐评分均显著降低,相比对照组,治疗组显著更低(P <0.05)。相比对照组,治疗组的不良反应发生率显著更低(P <0.05)。治疗后,相比对照组,治疗组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平显著更高;CD8^(+)水平显著更低(P <0.05)。治疗后,两组KPS评分均显著降低,相比对照组,治疗组显著更低;生活质量改善效果更优(P <0.05)。结论:应用温补脾肾法治疗肺癌免疫治疗相关性不良反应效果较佳,可显著改善中医证候积分和免疫功能,优化患者生活质量,降低不良反应发生率,值得推广。Objective: To observe the clinical efficacy of warming spleen and kidney therapy on immunotherapy related adverse reactions of lung cancer. Methods: From January 2020 to January 2021, a total of 98 cases were randomly divided into the control group and the treatment group. The control group was treated with oral prednisolone, and the treatment group was treated additionally by warming spleen and kidney therapy. The clinical efficacy, adverse reactions, TCM syndrome score, KPS score and immune function before and after treatment were compared between the two groups. Results: Compared with the control group, the total efficiency in the treatment group was significantly higher(P<0.05). After treatment, the scores of rash, diarrhea, liver function damage, nausea and vomiting in the two groups were significantly decreased, and in the treatment group were lower than those in the control group(P<0.05). Compared with the control group, the incidence of adverse reactions in the treatment group was significantly lower(P<0.05). After treatment, compared with the control group, the levels of CD3^(+), CD4^(+) and CD4^(+)/CD8^(+) in the treatment group were significantly higher;the level of CD8^(+) was significantly lower(P<0.05). After treatment, KPS score in the two groups were significantly decreased, and in the treatment group was lower than the control group;the improvement effect of quality of life was better(P<0.05). Conclusion: Warming spleen and kidney therapy on lung cancer immunotherapy related adverse reactions is effective, significantly improves TCM syndrome scores and immune function, optimizes quality of life, and reduces the incidence of adverse reactions, which is worthy of promotion.

关 键 词：肺癌 温补脾肾法 不良反应 

分 类 号：R273[医药卫生—中西医结合]